US FDA approves Eli Lilly's therapy for metastatic breast cancer-March 2024-www.financetom.com

US FDA approves Eli Lilly's therapy for metastatic breast cancer

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA approves Eli Lilly's therapy for metastatic breast cancer

Sep 25, 2025 11:20 AM

Sept 25 (Reuters) - Eli Lilly ( LLY ) said on Thursday

that the U.S. Food and Drug Administration has approved its

therapy for the treatment of metastatic breast cancer in

patients whose disease progressed after at least one line of

endocrine therapy.

Previous page： Edgewell to Sell Feminine Care Business for $340 Million Next page： Canada's Taseko Mines Q3 revenue rises, driven by improved Gibraltar copper production

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Edgewell to Sell Feminine Care Business for $340 Million

Nov 12, 2025

05:25 PM EST, 11/12/2025 (MT Newswires) -- Edgewell Personal Care ( EPC ) said late Wednesday it agreed to sell its feminine care business to Sweden's Essity for $340 million. The owner of the Stayfree and Carefree brands said it plans to use the proceeds from the sale to strengthen its balance sheet and focus on its core businesses. Edgewell...

Canada's Taseko Mines Q3 revenue rises, driven by improved Gibraltar copper production

Nov 12, 2025

Overview * Taseko Q3 rev at C$173.9 mln driven by improved Gibraltar copper production * Adjusted EPS for Q3 misses analyst expectations * Company reports net loss of ~C$28 mln for Q3 Outlook * Company expects 2025 copper production of 100 to 105 mln pounds * Taseko anticipates first copper cathode production at Florence Copper in early 2026 * Company...

I-80 Gold Q3 Adjusted Loss Narrows, Revenue Rises

Nov 12, 2025

05:28 PM EST, 11/12/2025 (MT Newswires) -- I-80 Gold ( IAUX ) reported a Q3 adjusted loss late Wednesday of $0.04 per share, narrowing from a loss of $0.08 a year earlier. Revenue for the three months ended Sept. 30 was $32 million, up from $11.5 million a year earlier. FactSet estimates were not readily available. ...

Amplitude Insider Bought Shares Worth $299,790, According to a Recent SEC Filing

Nov 12, 2025

05:27 PM EST, 11/12/2025 (MT Newswires) -- Andrew Casey, Chief Financial Officer, on November 07, 2025, executed a purchase for 30,000 shares in Amplitude (AMPL) for $299,790. Following the Form 4 filing with the SEC, Casey has control over a total of 1,160,608 Class A common shares of the company, with 1,160,608 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1866692/000203239025000004/xslF345X05/primarydocument.xml ...